Anemia in the elderly

HemaSphere

Volumn 2, Issue 3, 2018, Pages

  Girelli, Domenico ^a   Marchi, Giacomo ^a   Camaschella, Clara ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; VITAMIN D;

ANDROGEN DEFICIENCY; ANEMIA; ARTICLE; DEMOGRAPHY; HEMATOPOIESIS; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON DEFICIENCY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; VERY ELDERLY; VITAMIN D DEFICIENCY;

EID: 85062812870     PISSN: None     EISSN: 25729241     Source Type: Journal    
DOI: 10.1097/HS9.0000000000000040     Document Type: Article

References (150)

1. Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet 2009; 374:1196-1208.
2. Blanc B, Finch CA, Hallberg L, et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968; 405:1-40.
3. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747-1750.
4. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211-218.
5. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Vital Health Statist. 1994:1-407.
6. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood 2005; 106:740-745.
7. Perry GS, Byers T, Yip R, et al. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr 1992; 122:1417-1424.
8. Andres E, Serraj K, Federici L, et al. Anemia in elderly patients: new insight into an old disorder. Geriatr Gerontol Int 2013; 13: 519-527.
9. Nilsson-Ehle H, Jagenburg R, Landahl S, et al. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 2000; 65:297-305.
10. Nilsson-Ehle H, Jagenburg R, Landahl S, et al. Decline of blood haemoglobin in the aged: a longitudinal study of an urban Swedish population from age 70 to 81. Br J Haematol 1989; 71:437-442.
11. Zauber NP, Zauber AG. Hematologic data of healthy very old people. JAMA 1987; 257:2181-2184.
12. Erikson GA, Bodian DL, Rueda M, et al. Whole-genome sequencing of a healthy aging cohort. Cell 2016; 165:1002-1011.
13. Cevenini E, Cotichini R, Stazi MA, et al. Health status and 6 years survival of 552 90+ Italian sib-ships recruited within the EU Project GEHA (GEnetics of Healthy Ageing). Age (Dordr) 2014; 36:949-966.
14. Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107:3841-3846.
15. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the cardiovascular health study. Arch Intern Med 2005; 165:2214-2220.
16. Sheehan NA, Didelez V, Burton PR, et al. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008; 5:e177.
17. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999; 281:1714-1717.
18. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications and management. Blood 2017; 131:505-514.
19. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104:2263-2268.
20. Tettamanti M, Lucca U, Gandini F, et al. Prevalence, incidence and types of mild anemia in the elderly: the “Health and Anemia” population-based study. Haematologica 2010; 95:1849-1856.
21. Bach V, Schruckmayer G, Sam I, et al. Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging 2014; 9: 1187-1196.
22. Migone De Amicis M, Poggiali E, Motta I, et al. Anemia in elderly hospitalized patients: prevalence and clinical impact. Intern Emerg Med 2015; 10:581-586.
23. Sahin S, Tasar PT, Simsek H, et al. Prevalence of anemia and malnutrition and their association in elderly nursing home residents. Aging Clin Exp Res 2016; 28:857-862.
24. Deeruksa L, Sanchaisuriya K. Anemia in the elderly in Northeastern Thailand: a community-based study investigating prevalence, contributing factors, and hematologic features. Acta Haematol 2017; 138:96-102.
25. Gaskell H, Derry S, Andrew Moore R, et al. Prevalence of anaemia in older persons: systematic review. BMC Geriatr 2008; 8:1.
26. Engert A, Balduini C, Brand A, et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 2016; 101:115-208.
27. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43.
28. Penninx BW, Guralnik JM, Onder G, et al. Anemia and decline in physical performance among older persons. Am J Med 2003; 115:104-110.
29. Cecchi F, Pancani S, Vannetti F, et al. Hemoglobin concentration is associated with self-reported disability and reduced physical performance in a community dwelling population of nonagenarians: the Mugello Study. Intern Emerg Med 2017; 12:1167-1173.
30. Chaves PH, Semba RD, Leng SX, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2005; 60:729-735.
31. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52:719-724.
32. Penninx BW, Pluijm SM, Lips P, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53: 2106-2111.
33. Dharmarajan TS, Avula S, Norkus EP. Anemia increases risk for falls in hospitalized older adults: an evaluation of falls in 362 hospitalized, ambulatory, long-term care, and community patients. J Am Med Dir Assoc 2007; 8:e9-e15.
34. Duh MS, Mody SH, Lefebvre P, et al. Anaemia and the risk of injurious falls in a community-dwelling elderly population. Drugs Aging 2008; 25:325-334.
35. Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 2006; 119:327-334.
36. Lucca U, Tettamanti M, Mosconi P, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the “Health and Anemia” study. PLoS ONE 2008; 3:e1920.
37. Hong CH, Falvey C, Harris TB, et al. Anemia and risk of dementia in older adults: findings from the Health ABC study. Neurology 2013; 81:528-533.
38. Penninx BW, Pahor M, Woodman RC, et al. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 2006; 61:474-479.
39. Riva E, Tettamanti M, Mosconi P, et al. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica 2009; 94:22-28.
40. Riva E, Colombo R, Moreo G, et al. Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Arch Gerontol Geriatr 2017; 69:21-30.
41. Landi F, Russo A, Danese P, et al. Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc 2007; 8:322-327.
42. Shavelle RM, MacKenzie R, Paculdo DR. Anemia and mortality in older persons: does the type of anemia affect survival? Int J Hematol 2012; 95:248-256.
43. Kikuchi M, Inagaki T, Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Geriatr Soc 2001; 49:1226-1228.
44. Price EA, Mehra R, Holmes TH, et al. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 2011; 46:159-165.
45. Stauder R, Thein SL. Anemia in the elderly: clinical implications and new therapeutic concepts. Haematologica 2014; 99:1127-1130.
46. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
47. Weiss G. Anemia of chronic disorders: new diagnostic tools and new treatment strategies. Semin Hematol 2015; 52:313-320.
48. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014; 28:671-681.
49. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of Mammalian iron metabolism. Cell 2010; 142:24-38.
50. Muckenthaler MU, Rivella S, Hentze MW, et al. A red carpet for iron metabolism. Cell 2017; 168:344-361.
51. Del Vecchio L, Locatelli F. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. Expert Rev Hematol 2014; 7:495-506.
52. Cleland JG, Zhang J, Pellicori P, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol 2016; 1:539-547.
53. Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011; 58:1241-1251.
54. Schrier SL. Approach to the Adult Patient With Anemia. Wolters Kluwer: UpToDate; 2017.
55. Busti F, Campostrini N, Martinelli N, et al. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 2014; 5:83.
56. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-1551.
57. Cazzola M, Malcovati L, Invernizzi R. Myelodysplastic/myeloprolif-erative neoplasms. Hematology 2011; 2011:264-272.
58. Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011; 117:7121-7125.
59. McQuilten ZK, Wood EM, Polizzotto MN, et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 2014; 120: 1686-1694.
60. Buckstein R, Jang K, Friedlich J, et al. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res 2009; 33:1313-1318.
61. Mahmoud MY, Lugon M, Anderson CC. Unexplained macrocytosis in elderly patients. Age Ageing 1996; 25:310-312.
62. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122:3616-3627.
63. Bacher U, Kohlmann A, Haferlach T. Mutational profiling in patients with MDS: ready for every-day use in the clinic? Best Pract Res Clin Haematol 2015; 28:32-42.
64. Albitar F, Ma W, Diep K, et al. Deep sequencing of cell-free peripheral blood DNA as a reliable method for confirming the diagnosis of myelodysplastic syndrome. Genet Test Mol Biomarkers 2016; 20:341-345.
65. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496-2506.
66. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget 2017; 8:73483-73500.
67. Mies A, Platzbecker U. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-beta superfamily inhibitors. Semin Hematol 2017; 54:141-146.
68. Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017; 18:1338-1347.
69. Ferrucci L, Maggio M, Bandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166:1380-1388.
70. Waalen J, von Lohneysen K, Lee P, et al. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011; 87:107-116.
71. Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med 2017; 177:480-490.
72. Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood 2016; 127:2809-2813.
73. Latour C, Kautz L, Besson-Fournier C, et al. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology 2014; 59:683-694.
74. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76:1536-1538.
75. Timpini A, Pini L, Tantucci C, et al. Vitamin D and health status in elderly. Intern Emerg Med 2011; 6:11-21.
76. Monlezun DJ, Camargo CAJr, Mullen JT, et al. Vitamin D status and the risk of anemia in community-dwelling adults: results from the National Health and Nutrition Examination Survey 2001-2006. Medicine (Baltimore) 2015; 94:e1799.
77. Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10:482-496.
78. Kiss Z, Ambrus C, Almasi C, et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 2011; 117:c373-c378.
79. Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 2014; 25:564-572.
80. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908:244-254.
81. Youm YH, Grant RW, McCabe LR, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 2013; 18:519-532.
82. Franceschi C, Garagnani P, Vitale G, et al. Inflammaging and “Garb-aging”. Trends Endocrinol Metab 2017; 28:199-212.
83. Leng S, Chaves P, Koenig K, et al. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 2002; 50:1268-1271.
84. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-788.
85. Traglia M, Girelli D, Biino G, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011; 48:629-634.
86. den Elzen WP, de Craen AJ, Wiegerinck ET, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus study. Haematologica 2013; 98:448-454.
87. Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 2005; 53:1360-1365.
88. Kario K, Matsuo T, Nakao K. Serum erythropoietin levels in the elderly. Gerontology 1991; 37:345-348.
89. Ferrucci L, Guralnik JM, Bandinelli S, et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 2007; 136:849-855.
90. Vanasse GJ, Berliner N. Anemia in elderly patients: an emerging problem for the 21st century. Hematology 2010; 2010:271-275.
91. Chung SS, Park CY. Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Adv 2017; 1:2572-2578.
92. Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol 2017; 54:43-50.
93. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477-2487.
94. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488-2498.
95. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017; 129:3371-3378.
96. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126:9-16.
97. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377: 111-121.
98. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355:842-847.
99. Swirski FK. Inflammation and CVD in 2017: from clonal haemato-poiesis to the CANTOS trial. Nat Rev Cardiol 2018; 15:79-80.
100. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372:1832-1843.
101. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27:443-454.
102. Petrosyan I, Blaison G, Andres E, et al. Anaemia in the elderly: an aetiologic profile of a prospective cohort of 95 hospitalised patients. Eur J Intern Med 2012; 23:524-528.
103. Hillman R. Iron-Deficiency Anemia. Hematology in Clinical Practice. 5th ed. New York, NY: McGraw-Hill Medical; 2011.
104. Schrier SL. Causes and Diagnosis of Iron Deficiency and Iron Deficiency Anemia in Adults. Wolters Kluwer: UpToDate; 2017.
105. Guyatt GH, Patterson C, Ali M, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 1990; 88:205-209.
106. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:1052-1057.
107. Karlsson T. Evaluation of a competitive hepcidin ELISA assay in the differential diagnosis of iron deficiency anaemia with concurrent inflammation and anaemia of inflammation in elderly patients. J Inflamm (Lond) 2017; 14:21.
108. De Franceschi L, Iolascon A, Taher A, et al. Clinical management of iron deficiency anemia in adults: systemic review on advances in diagnosis and treatment. Eur J Intern Med 2017; 42:16-23.
109. Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012; 82:952-960.
110. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 89:28-39.
111. von Haehling S, Jankowska EA, van Veldhuisen DJ, et al. Iron deficiency and cardiovascular disease. Nat Rev Cardiol 2015; 12: 659-669.
112. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31:1872-1880.
113. Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol 2018; 107: 16-30.
114. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013; 165:575-582.
115. Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res 2016; 119:159-176.
116. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436-2448.
117. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36:657-668.
118. Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013; 15:1267-1276.
119. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18:786-795.
120. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136:1374-1383.
121. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-2200.
122. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70:776-803.
123. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol 2017; 33: 1342-1433.
124. Antony AC. Hoffman R, Benz EJ, Shattil SJ, et al. Megaloblastic anemias. Hematology: Basic Principles and Practice 4th ed. New York, NY: Churchill Livingstone; 2005; 519.
125. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med 2013; 368:149-160.
126. Lewerin C, Jacobsson S, Lindstedt G, et al. Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy. Scand J Gastroenterol 2008; 43:1050-1056.
127. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992; 40:1197-1204.
128. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998; 92: 1191-1198.
129. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 2017; 317:1958-1966.
130. Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011; 28:509-518.
131. Mannucci PM, Nobili A, Investigators R. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med 2014; 9:723-734.
132. Valenti L, Messa P, Pelusi S, et al. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med 2014; 52:613-619.
133. Lee SW, Kim JM, Lim HJ, et al. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci Rep 2017; 7:4260.
134. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88:97-101.
135. Poli M, Asperti M, Ruzzenenti P, et al. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 2014; 5:86.
136. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 2014; 35:155-161.
137. van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 2014; 124:2643-2646.
138. Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol 2016; 173:1580-1588.
139. Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the antihepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013; 121:2311-2315.
140. Hohlbaum AM, Gille H, Trentmann S, et al. Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey. Br J Pharmacol 2018; 175:1054-1065.
141. Poli M, Girelli D, Campostrini N, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011; 117:997-1004.
142. Poli M, Asperti M, Naggi A, et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014; 123:1564-1573.
143. Poli M, Asperti M, Ruzzenenti P, et al. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem Pharmacol 2014; 92: 467-475.
144. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc 2007; 55:1557-1565.
145. Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology 2016; 2016:462-469.
146. Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017; 69:815-826.
147. Bolton-Maggs PH, Cohen H. Serious hazards of transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163:303-314.
148. Murphy MF, Estcourt L, Goodnough LT. Blood transfusion strategies in elderly patients. Lancet Haematol 2017; 4:e453-e454.
149. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60:1309-1316.
150. Balducci L. Epidemiology of anemia in the elderly: information on diagnostic evaluation. J Am Geriatr Soc 2003; 51:S2-S9.